Revolution Medicines Files 8-K

TL;DR

REVMD filed an 8-K on 9/10/25 for 'Other Events' - details TBD.

AI Summary

On September 10, 2025, Revolution Medicines, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Revolution Medicines, Inc. has reported an event requiring public disclosure to the SEC, though the specifics are not detailed in this excerpt.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

• Revolution Medicines, Inc. (company) — Registrant
• September 10, 2025 (date) — Date of earliest event reported
• 001-39219 (other) — Commission File Number
• 47-2029180 (other) — IRS Employer Identification No.
• 700 Saginaw Drive, Redwood City, California 94063 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq

Filing Documents

• d947102d8k.htm (8-K) — 91KB
• g947102g09k09.jpg (GRAPHIC) — 70KB
• g947102g10k10.jpg (GRAPHIC) — 42KB
• g947102g11k11.jpg (GRAPHIC) — 44KB
• g947102g12k12.jpg (GRAPHIC) — 67KB
• g947102g13k13.jpg (GRAPHIC) — 62KB
• 0001193125-25-200078.txt ( ) — 949KB
• rvmdw-20250910.xsd (EX-101.SCH) — 4KB
• rvmdw-20250910_def.xml (EX-101.DEF) — 13KB
• rvmdw-20250910_lab.xml (EX-101.LAB) — 21KB
• rvmdw-20250910_pre.xml (EX-101.PRE) — 14KB
• d947102d8k_htm.xml (XML) — 6KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding the Company's belief that preliminary data observations from the RMC-6236-001 Study support the continued development of daraxonrasib in patients with RAS-mutant PDAC and preliminary data observations from the RMC-6236 Study and RMC-GI-102 Study as of the 1L Data Cutoff Date support the company's plans to initiate RASolute 303, a global, randomized Phase 3 trial in patients with 1L metastatic PDAC; and the Company's plans to initiate a global, randomized Phase 3 trial comparing daraxonrasib with and without GnP against a GnP monotherapy in patients with RAS-mutant PDAC in the 1L setting. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company's development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation: risks and uncertainties inherent in the drug development process, in performing clinical studies, and in the process of designing and conducting clinical trials; risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results; the regulatory approval processes; the timing of regulatory filings; the challenges associated with manufacturing drug products; the Company's ability to successfully establish, protect, and defend its i

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: September 10, 2025 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR